Physicians' Academy for Cardiovascular Education
Watch the discussion by the expert faculty of the symposium, chaired by prof. John Kastelein, Amsterdam, The Netherlands and speakers prof. Kausik Ray, London, UK, Derek Connolly, Birmingham, UK and prof. Christie Ballantyne, Houston, TX, USA.
Real-world evidence shows that the majority of patients do not achieve their LDL-c target goals. Where do we fall short in the need for combination therapy?
The new therapeutic options for LDL-c lowering, bempedoic acid and inclisiran, are discussed by prof. Ballantyne. How do these drugs lower LDL-c and what are the findings in phase III programs?
Why should combination therapy, including PCSK9 monoclonal antibodies, be given to ACS patients? Derek Connolly sums up the evidence. With question to test your knowledge.
Slides as educational service to PACE members and meeting participants.
Slides as educational service to PACE members and meeting participants.
Slides as educational service to PACE members and meeting participants.
Prof. Ray explains why monotherapy is not sufficient, and thus combination therapy is needed to reach LDL-c goals in patients with high CV risk.
